News Releases

Date Title  
Toggle Summary Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
SAN DIEGO , May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the New Drug Application (NDA) was resubmitted to
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
SAN DIEGO , May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the New Drug Application (NDA) was resubmitted to
Toggle Summary Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
SAN DIEGO , May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
SAN DIEGO , May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
Toggle Summary Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update
Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call today at 2 p.m. PDT / 5 p.m. EDT SAN DIEGO , April 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals
Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update
Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call today at 2 p.m. PDT / 5 p.m. EDT SAN DIEGO , April 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals
Toggle Summary Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
SAN DIEGO , April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
SAN DIEGO , April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
Toggle Summary Adamis Pharmaceuticals Provides an Update on ZIMHI™
SAN DIEGO , April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its ZIMHI ™ high-dose naloxone injection product intended for the treatment of opioid overdose.
Adamis Pharmaceuticals Provides an Update on ZIMHI™
SAN DIEGO , April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its ZIMHI ™ high-dose naloxone injection product intended for the treatment of opioid overdose.
Toggle Summary Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model
SAN DIEGO , March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes
Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model
SAN DIEGO , March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes
Toggle Summary Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) --   Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety review of the Company’s Investigational New Drug (“IND”) application and has concluded that
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) --   Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety review of the Company’s Investigational New Drug (“IND”) application and has concluded that
Toggle Summary Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate
SAN DIEGO , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI ™  high dose naloxone injection product candidate, intended for the treatment of
Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate
SAN DIEGO , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI ™  high dose naloxone injection product candidate, intended for the treatment of
Toggle Summary Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
SAN DIEGO , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its common stock, including 6,081,081 shares sold pursuant to the exercise in full of the underwriters' option to
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
SAN DIEGO , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its common stock, including 6,081,081 shares sold pursuant to the exercise in full of the underwriters' option to
Toggle Summary Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Jan. 29, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Jan. 29, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced
Toggle Summary Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced
Toggle Summary Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients
SAN DIEGO , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) in collaboration with the Human Immune Monitoring Center at Stanford University have conducted a study to investigate the effects of Tempol on immune cells from COVID-19 patients.
Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients
SAN DIEGO , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) in collaboration with the Human Immune Monitoring Center at Stanford University have conducted a study to investigate the effects of Tempol on immune cells from COVID-19 patients.
Toggle Summary Adamis Pharmaceuticals Provides Update On Its US Compounding Business
SAN DIEGO , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Adamis   Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a non-binding letter of intent with a potential buyer for sale of substantially all of the assets of its US Compounding Inc. (USC) subsidiary.
Adamis Pharmaceuticals Provides Update On Its US Compounding Business
SAN DIEGO , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Adamis   Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a non-binding letter of intent with a potential buyer for sale of substantially all of the assets of its US Compounding Inc. (USC) subsidiary.
Toggle Summary SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
SAN DIEGO , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Adamis   Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its SYMJEPI ® (epinephrine) Injection products are now available to members of the Walgreens Prescription Savings Club program, for a discounted price of $99.99 for a two-pack, the
SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
SAN DIEGO , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Adamis   Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its SYMJEPI ® (epinephrine) Injection products are now available to members of the Walgreens Prescription Savings Club program, for a discounted price of $99.99 for a two-pack, the
Toggle Summary Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
SAN DIEGO , Jan. 20, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19).
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
SAN DIEGO , Jan. 20, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19).
Toggle Summary Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter
SAN DIEGO , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced a planned response to a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), regarding its New Drug Application (NDA) for Adamis’ ZIMHI ™ high dose naloxone
Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter
SAN DIEGO , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced a planned response to a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), regarding its New Drug Application (NDA) for Adamis’ ZIMHI ™ high dose naloxone
Toggle Summary Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI
SAN DIEGO , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis   Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13 th , it received a Complete Response Letter (CRL) from the U.S.
Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI
SAN DIEGO , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis   Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13 th , it received a Complete Response Letter (CRL) from the U.S.
Toggle Summary Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
SAN DIEGO , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis   Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals ,
Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
SAN DIEGO , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis   Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals ,
Toggle Summary Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business Update
SAN DIEGO , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, November 9, 2020 at 2:00 pm Pacific Time to discuss its financial and operating results for the third quarter of 2020
Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business Update
SAN DIEGO , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, November 9, 2020 at 2:00 pm Pacific Time to discuss its financial and operating results for the third quarter of 2020
Toggle Summary Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,
Toggle Summary Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,
Toggle Summary Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
SAN DIEGO , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the results of its reconvened 2020 annual meeting of stockholders which was initially held August 20, 2020 , and was adjourned until September 3, 2020 .  At the reconvened meeting, the
Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
SAN DIEGO , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the results of its reconvened 2020 annual meeting of stockholders which was initially held August 20, 2020 , and was adjourned until September 3, 2020 .  At the reconvened meeting, the
Toggle Summary Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders and Proposals
SAN DIEGO , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided additional information concerning the proposals to be considered at its adjourned 2020 annual meeting of stockholders, which will resume on September 3, 2020 at 10:00 a.m.
Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders and Proposals
SAN DIEGO , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided additional information concerning the proposals to be considered at its adjourned 2020 annual meeting of stockholders, which will resume on September 3, 2020 at 10:00 a.m.
Toggle Summary Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
SAN DIEGO , Aug. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2020 Annual Meeting of Stockholders (“Annual Meeting”), convened on Thursday, August 20, 2020 , has been adjourned and will resume on September 3, 2020 at 10:00 a.m.
Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
SAN DIEGO , Aug. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2020 Annual Meeting of Stockholders (“Annual Meeting”), convened on Thursday, August 20, 2020 , has been adjourned and will resume on September 3, 2020 at 10:00 a.m.
Toggle Summary Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
SAN DIEGO, Calif. , Aug. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2020 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals
Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
SAN DIEGO, Calif. , Aug. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2020 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals